KLRS
$8.52
Pre-MarketAs of Mar 17, 8:00 PM UTC
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases.
Recent News
We Think Kalaris Therapeutics (NASDAQ:KLRS) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Kalaris Therapeutics, Inc.'s (NASDAQ:KLRS) biggest owners are private equity firms who got richer after stock soared 24% last week
Key Insights Kalaris Therapeutics' significant private equity firms ownership suggests that the key decisions are...
Kalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should Know
Kalaris Therapeutics Inc. (KLRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
We're Hopeful That Kalaris Therapeutics (NASDAQ:KLRS) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...